Nucleus Capital is an early-stage venture firm focused on planetary and human health. Its connection to the psychedelic field is participation in the US$3.0 million 2023 pre-seed round of Biomia, an early-stage biotechnology company.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage focus is not listed yet. Psychedelic-market posture: Psychedelic-Adjacent Focus.
Public Portfolio Examples
- BiomiaPre-seed financing - $3.0 million - Sep 26, 2023
Created from documented participation in 1 psychedelic financing round. Profile details beyond documented deals are unverified.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Stage focus is not listed yet.
Investment Focus Areas
Focus areas are not listed yet.
Recorded Investments
Sep 26, 2023
Pre-seed financing - $3.0 million
Biomia Secures $3.0 Million in Pre-seed Financing